Patents by Inventor Dasha NELIDOVA

Dasha NELIDOVA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutical tools and methods for treating blindness by targeting photoreceptors
    Patent number: 11931427
    Abstract: The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 19, 2024
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Josephine Juettner, Dasha Nelidova, Botond Roska
  • NOVEL THERAPEUTICAL TOOLS AND METHODS USING TEMPERATURE-SENSITIVE RECEPTORS FOR TREATING BLINDNESS
    Publication number: 20230103783
    Abstract: The present inventions relates to a method for vision restoration comprising the steps of expressing a temperature-sensitive transient receptor potential (TRP) channel having an extracellular tag in the retina of a subject and of contacting said retina with a nanomaterial conjugated to a molecule specifically binding to said extracellular tag, wherein said nanomaterial generates heat by absorbing radiations of a specific wavelength. And reagents therefor.
    Type: Application
    Filed: February 18, 2021
    Publication date: April 6, 2023
    Inventors: Dasha NELIDOVA, Botond ROSKA
  • NOVEL THERAPEUTICAL TOOLS AND METHODS FOR TREATING BLINDNESS BY TARGETING PHOTORECEPTORS
    Publication number: 20210085804
    Abstract: The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
    Type: Application
    Filed: October 30, 2020
    Publication date: March 25, 2021
    Inventors: Josephine JUETTNER, Dasha NELIDOVA, Botond ROSKA
  • Therapeutical tools and methods for treating blindness by targeting photoreceptors
    Patent number: 10857241
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: December 8, 2020
    Assignee: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Josephine Juettner, Dasha Nelidova, Botond Roska
  • NOVEL THERAPEUTICAL TOOLS AND METHODS FOR TREATING BLINDNESS BY TARGETING PHOTORECEPTORS
    Publication number: 20180256753
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
    Type: Application
    Filed: September 13, 2016
    Publication date: September 13, 2018
    Applicant: Friedrich Miescher Institute for Biomedical Research
    Inventors: Josephine JUETTNER, Dasha NELIDOVA, Botond ROSKA